A Phase 3 interventional study of Momelotinib and Ruxolitinib in Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis and Post-Essential Thrombocythemia Myelofibrosis, sponsored by Sierra Oncology LLC - a GSK company. Completed at 114 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-12.
Sponsored by Sierra Oncology LLC - a GSK company (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing momelotinib in Primary Myelofibrosis — 3 open to participants now, 4 under way, none of them phase 3. momelotinib · Primary Myelofibrosis.
Among the 12 studies testing momelotinib in Primary Myelofibrosis, this one has the largest enrollment, is the only one that started in 2013, is one of 3 in phase 3, and was the 4th registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.
Browse Primary Myelofibrosis studies →3 of the 12 studies testing momelotinib in Primary Myelofibrosis are open now, in 6 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
GlaxoSmithKline · Sites in United States, Canada, France and 3 more countries
Ages 18+
SWOG Cancer Research Network
Ages 18+
By country, each count listing its studies:
momelotinib: first FDA approval 2023 (OJJAARA), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 3 · Phase 4 1
First in 2009; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 432 is above the median of 43 across 490 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 138 across the 12 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Sierra Oncology LLC - a GSK company, one of the names counted as GlaxoSmithKline. Under that name alone:
Sierra Oncology LLC - a GSK company is the lead sponsor of 19 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
11 studies in Primary Myelofibrosis by GlaxoSmithKline: 1 open now, 2 under way, none of them phase 3. Of 8 finished, 5 (63%) have results posted.
Among the 11 studies in Primary Myelofibrosis by GlaxoSmithKline, this one has the largest enrollment of the 10 interventional ones that give a count, is the only one that started in 2013, is one of 3 in phase 3, and was the 4th registered.
GlaxoSmithKline’s Primary Myelofibrosis studies by the year they started, since 2009.
2 of the studies testing momelotinib in Primary Myelofibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03441113GlaxoSmithKlineExtended Access of Momelotinib in Adults With Myelofibrosis | 2026-12-11 |
| NCT06517875GlaxoSmithKlineStudy of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis | 2027-03-16 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing momelotinib in Primary Myelofibrosis, from their registry updates:
Among GlaxoSmithKline’s 11 in Primary Myelofibrosis:
This tab as a report to print or save as PDF → With an account.
This study is to determine the efficacy of momelotinib (MMB) versus ruxolitinib (RUX) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF) who have not yet received treatment with a Janus kinase inhibitor (JAK inhibitor).
Participants will be randomized to receive either MMB or ruxolitinib for 24 weeks during a double-blind treatment phase, after which they will be eligible to receive open-label MMB for up to an additional 216 weeks. After discontinuation of study medication, assessments will continue for 12 additional weeks, after which participants will be contacted for survival follow-up approximately every 6 months for up to 5 years from the date of enrollment or until study termination. For those participants planning to continue treatment with MMB following the end of the study, the Early Study Drug Discontinuation (ESDD), 30-day, 12-Week, and survival follow-up visits are not required.
Key Inclusion Criteria:
Acceptable laboratory assessment obtained within 14 days prior to the first dose of study drug:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive momelotinib plus placebo to match ruxolitinib.
Drug: Momelotinib · Drug: Placebo to match ruxolitinib
Participants will receive ruxolitinib plus placebo to match momelotinib.
Drug: Ruxolitinib · Drug: Placebo to match momelotinib
Momelotinib tablet administered orally once daily
Also known as: GS-0387, CYT387
Ruxolitinib tablets administered orally twice daily
Placebo to match momelotinib tablets administered orally once daily
Placebo to match ruxolitinib tablets administered orally twice daily
Splenic Response Rate at Week 24
Splenic response rate at Week 24 is defined as the percentage of participants who achieved a spleen volume reduction of ≥ 35% from baseline at the Week 24 assessment as measured by MRI or CT.
Time frame: Week 24
Total Symptom Score (TSS) Response Rate at Week 24
Total symptom score (TSS) is defined as the percentage of participants who achieved a ≥50% reduction in TSS at Week 24 versus baseline as measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) v2.0 diary. Response rate was calculated using the average of the daily TSS from a consecutive 28-day period prior to Week 24, which had ≥20 daily TSS available. The modified MPN-SAF patient-reported outcome instrument consisted of 8 items assessing worst daily incidence of tiredness, filling up quickly, abdominal discomfort, night sweats, itching, bone pain, pain under ribs on left side, and inactivity. Scoring of the Total Symptom Score (TSS), in this study was based on 7 of these items, (range of 0-70,), excluding inactivity. These items assess the impact experienced by the participant in the 24 hours prior to completing the questionnaire. All items are measured using a 0 to 10 Numeric Rating Scale, with 0 corresponding to "Absent" and 10 being the worse
Time frame: Week 24
Rate of Red Blood Cell (RBC) Transfusions in the Double-blind Phase, (the Average Number of RBC Units Transfused Per Month Not Associated With Overt Bleeding)
Rate of RBC transfusion was defined as the average number of RBC units transfused not associated with clinically overt bleeding per subject-month during the double-blind phase.
Time frame: Baseline to Week 24
RBC Transfusion Independence Rate at Week 24, (Defined as Absence of RBC Transfusions and no Hemoglobin Level Below 8 g/dL in the 12 Weeks Prior to Week 24, Excluding Cases Associated With Clinically Overt Bleeding)
RBC transfusion independence is the percentage of participants who are transfusion independent at Week 24, defined as absence of RBC transfusions and no hemoglobin level below 8 g/dL in the 12 weeks prior to Week 24, excluding cases associated with clinically overt bleeding.
Time frame: Week 24
RBC Transfusion Dependence Rate at Week 24. (Defined as Having Had at Least 4 Units of RBC Transfusions, or a Hemoglobin Level Below 8 g/dL in 8 Weeks Prior to Week 24 (Excluding Cases Associated With Clinically Overt Bleeding)).
RBC transfusion dependence is the percentage of participants who are transfusion dependent at Week 24, defined as having had at least 4 units of RBC transfusions, or a hemoglobin level below 8 g/dL in 8 weeks prior to Week 24 (excluding cases associated with clinically overt bleeding). Participants with the last double-blind phase participation date prior to Day 162 (ie. missing at Week 24) were considered transfusion dependent at Week 24.
Time frame: Week 24
432 participants were randomized at 131 centers in 22 countries.
| Milestone | Momelotinib (MMB) | Ruxolitinib (RUX) | MMB to MMB | RUX to MMB |
|---|---|---|---|---|
| Started | 215 | 217 | 0 | 0 |
| Completed | 188 | 208 | 0 | 0 |
| Not completed | 27 | 9 | 0 | 0 |
| Withdrew: Adverse event | 10 | 4 | 0 | 0 |
| Withdrew: Death | 5 | 2 | 0 | 0 |
| Withdrew: Physician decision | 5 | 1 | 0 | 0 |
| Withdrew: Subject decision | 4 | 2 | 0 | 0 |
| Withdrew: Disease progression | 2 | 0 | 0 | 0 |
| Withdrew: Symptomatic spleen growth | 1 | 0 | 0 | 0 |
| Milestone | Momelotinib (MMB) | Ruxolitinib (RUX) | MMB to MMB | RUX to MMB |
|---|---|---|---|---|
| Started | 0 | 0 | 171 | 197 |
| Completed | 0 | 0 | 1 | 0 |
| Not completed | 0 | 0 | 170 | 197 |
| Withdrew: Transferred to study sra-mmb-4365 | 0 | 0 | 52 | 62 |
| Withdrew: Adverse event | 0 | 0 | 37 | 49 |
| Withdrew: Disease progression | 0 | 0 | 26 | 27 |
| Withdrew: Lack of efficacy | 0 | 0 | 17 | 19 |
| Withdrew: Subject decision | 0 | 0 | 14 | 15 |
| Withdrew: Death | 0 | 0 | 13 | 11 |
| Withdrew: Physician decision | 0 | 0 | 9 | 14 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 2 | 0 |
Splenic response rate at Week 24 is defined as the percentage of participants who achieved a spleen volume reduction of ≥ 35% from baseline at the Week 24 assessment as measured by MRI or CT.
| Participants | Momelotinib (MMB) | Ruxolitinib (RUX) |
|---|---|---|
| Responder | 57 | 64 |
| Nonresponder | 158 | 153 |
Total symptom score (TSS) is defined as the percentage of participants who achieved a ≥50% reduction in TSS at Week 24 versus baseline as measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) v2.0 diary. Response rate was calculated using the average of the daily TSS from a consecutive 28-day period prior to Week 24, which had ≥20 daily TSS available. The modified MPN-SAF patient-reported outcome instrument consisted of 8 items assessing worst daily incidence of tiredness, filling up quickly, abdominal discomfort, night sweats, itching, bone pain, pain under ribs on left side, and inactivity. Scoring of the Total Symptom Score (TSS), in this study was based on 7 of these items, (range of 0-70,), excluding inactivity. These items assess the impact experienced by the participant in the 24 hours prior to completing the questionnaire. All items are measured using a 0 to 10 Numeric Rating Scale, with 0 corresponding to "Absent" and 10 being the worse
| Participants | Momelotinib (MMB) | Ruxolitinib (RUX) |
|---|---|---|
| Responder | 60 | 89 |
| Nonresponder | 151 | 122 |
Rate of RBC transfusion was defined as the average number of RBC units transfused not associated with clinically overt bleeding per subject-month during the double-blind phase.
| units/month | Momelotinib (MMB) | Ruxolitinib (RUX) |
|---|---|---|
| Rate of Red Blood Cell (RBC) Transfusions in the Double-blind Phase, (the Average Number of RBC Units Transfused Per Month Not Associated With Overt Bleeding) | 0.0 (0.0 to 0.2) | 0.4 (0.0 to 1.5) |
RBC transfusion independence is the percentage of participants who are transfusion independent at Week 24, defined as absence of RBC transfusions and no hemoglobin level below 8 g/dL in the 12 weeks prior to Week 24, excluding cases associated with clinically overt bleeding.
| Participants | Momelotinib (MMB) | Ruxolitinib (RUX) |
|---|---|---|
| Responder | 143 | 107 |
| Nonresponder | 72 | 110 |
RBC transfusion dependence is the percentage of participants who are transfusion dependent at Week 24, defined as having had at least 4 units of RBC transfusions, or a hemoglobin level below 8 g/dL in 8 weeks prior to Week 24 (excluding cases associated with clinically overt bleeding). Participants with the last double-blind phase participation date prior to Day 162 (ie. missing at Week 24) were considered transfusion dependent at Week 24.
| Participants | Momelotinib (MMB) | Ruxolitinib (RUX) |
|---|---|---|
| Dependent | 65 | 87 |
| Nondependent | 150 | 130 |
Collected over Serious and other Adverse events were recorded that occurred from initiation of investigational product (IP) until 30 days after the last administration of IP regardless of cause or relationship. Serious events are monitored up to 12 weeks and all-cause mortality was assessed for up to 5 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Momelotinib (MMB) | 8/214 (3.7%) | 49/214 (22.9%) | 197/214 (92.1%) |
| Ruxolitinib (RUX) | 6/216 (2.8%) | 39/216 (18.1%) | 206/216 (95.4%) |
| MMB to MMB | 44/171 (25.7%) | 79/171 (46.2%) | 153/171 (89.5%) |
| RUX to MMB | 54/197 (27.4%) | 79/197 (40.1%) | 188/197 (95.4%) |
| Event | Momelotinib (MMB) | Ruxolitinib (RUX) | MMB to MMB | RUX to MMB |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 4/214 | 3/216 | 16/171 | 9/197 |
| AnaemiaBlood and lymphatic system disorders | 4/214 | 8/216 | 7/171 | 4/197 |
| SepsisInfections and infestations | 2/214 | 1/216 | 6/171 | 1/197 |
| Cardiac failureCardiac disorders | 2/214 | 0/216 | 5/171 | 2/197 |
| Urinary tract infectionInfections and infestations | 0/214 | 2/216 | 2/171 | 5/197 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/214 | 3/216 | 0/171 | 4/197 |
| Atrial fibrillationCardiac disorders | 4/214 | 1/216 | 3/171 | 4/197 |
| DiarrhoeaGastrointestinal disorders | 4/214 | 1/216 | 0/171 | 4/197 |
| Acute kidney injuryRenal and urinary disorders | 1/214 | 1/216 | 3/171 | 4/197 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/214 | 0/216 | 1/171 | 4/197 |
| Event | Momelotinib (MMB) | Ruxolitinib (RUX) | MMB to MMB | RUX to MMB |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 30/214 | 79/216 | 38/171 | 29/197 |
| ThrombocytopeniaBlood and lymphatic system disorders | 40/214 | 62/216 | 29/171 | 39/197 |
| HeadacheNervous system disorders | 38/214 | 43/216 | 13/171 | 24/197 |
| NauseaGastrointestinal disorders | 33/214 | 8/216 | 16/171 | 39/197 |
| DiarrhoeaGastrointestinal disorders | 36/214 | 42/216 | 30/171 | 37/197 |
| FatigueGeneral disorders | 31/214 | 26/216 | 17/171 | 38/197 |
| CoughRespiratory, thoracic and mediastinal disorders | 18/214 | 17/216 | 23/171 | 34/197 |
| DizzinessNervous system disorders | 34/214 | 25/216 | 17/171 | 25/197 |
| Peripheral sensory neuropathyNervous system disorders | 20/214 | 12/216 | 15/171 | 28/197 |
| Abdominal painGastrointestinal disorders | 21/214 | 24/216 | 13/171 | 26/197 |
| Age, Categorical(Participants) | Momelotinib (MMB) | Ruxolitinib (RUX) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 90 | 95 | 185 |
| >=65 years | 125 | 122 | 247 |
| Age, Continuous(years) | Momelotinib (MMB) | Ruxolitinib (RUX) | Total |
|---|---|---|---|
| Median | 67 (28 to 85) | 66 (25 to 86) | 66 (25 to 86) |
| Sex: Female, Male(Participants) | Momelotinib (MMB) | Ruxolitinib (RUX) | Total |
|---|---|---|---|
| Female | 91 | 97 | 188 |
| Male | 124 | 120 | 244 |
| Ethnicity (NIH/OMB)(Participants) | Momelotinib (MMB) | Ruxolitinib (RUX) | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 4 | 10 |
| Not Hispanic or Latino | 191 | 194 | 385 |
| Unknown or Not Reported | 18 | 19 | 37 |
| Race/Ethnicity, Customized(Participants) | Momelotinib (MMB) | Ruxolitinib (RUX) | Total |
|---|---|---|---|
| White | 179 | 178 | 357 |
| Black or African American | 2 | 2 | 4 |
| Asian | 17 | 20 | 37 |
| Not Permitted | 15 | 16 | 31 |
| Other | 2 | 1 | 3 |
| Transfusion Dependent(Participants) | Momelotinib (MMB) | Ruxolitinib (RUX) | Total |
|---|---|---|---|
| Yes | 53 | 52 | 105 |
| No | 162 | 165 | 327 |
| Platelet Count (10^9/L)(Participants) | Momelotinib (MMB) | Ruxolitinib (RUX) | Total |
|---|---|---|---|
| < 100 | 18 | 23 | 41 |
| >= 100 and <= 200 | 66 | 63 | 129 |
| > 200 | 131 | 131 | 262 |
| Weight(kg) | Momelotinib (MMB) | Ruxolitinib (RUX) | Total |
|---|---|---|---|
| Median | 69.3 (62.9 to 80.0) | 71.4 (62.5 to 83.4) | 70.0 (62.8 to 82.0) |
3 further baseline measures are reported on the registry.
Showing the first 100 of 114 sites across 22 countries. Choose a country and city above to see the rest.
Ran from Dec 2013 to primary completion in Sep 2016, 33 months.
Results were first posted in May 2023, 6 years 8 months after primary completion. A results delay was requested in Jan 2017.
Of 22 phase 3 interventional studies under Primary Myelofibrosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 68. This study's 33 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Momelotinib
Sierra Oncology LLC - a GSK company →